Saturday 17 October 2026
Export LKFT’s income statement to Excel — free account
Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
29.90
0.03
−0.10%
Follow LKFT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 80.17 | 0.00 | 0.00 | 0.00 | 0.00 | 11.59 | 0.00 |
Piotroski F-Score |
7 | 1 | 3 | 5 | 1 | 3 | 2 | 5 | 4 | 6 |
P/S ratio |
47.10 | 50.39 | 12.74 | 11.88 | 10.63 | 6.30 | 5.47 | 4.69 | 3.28 | 4.92 |
Altman Z-Score |
5.86 | 9.60 | 11.54 | 3.37 | 2.01 | 1.60 | 1.47 | 1.81 | 1.55 | 8.43 |
P/FCF ratio |
20.29 | 37.59 | 0.00 | 3.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.52 | 8.10 | 9.83 | 7.02 | 5.95 | 6.07 | 5.63 | 6.74 | 6.81 | 26.33 |
Beneish M-Score |
(2.31) | (1.60) | (1.63) | (3.53) | (0.19) | (2.47) | (2.43) | (1.39) | (1.32) | 0.34 |
P/Operating CF |
10.41 | (43.14) | (82.58) | (110.41) | (201.04) | (18.51) | (14.26) | (7.38) | (6.32) | (8.77) |
P/B ratio |
3.59 | 3.59 | 3.33 | 3.70 | 2.11 | 1.15 | 1.09 | 0.95 | 0.58 | 0.75 |
Price to Tangible BV |
3.60 | 3.59 | 3.34 | 3.73 | 2.17 | 1.18 | 1.20 | 1.03 | 0.63 | 0.75 |
EV/Sales |
29.35 | 33.88 | 8.68 | 5.45 | 0.95 | (3.37) | (2.60) | (2.44) | (3.44) | (3.21) |
EV/EBITDA |
62.85 | 0.00 | 0.00 | 12.95 | 0.00 | 11.32 | 5.73 | 5.86 | 7.32 | 3.70 |
EV/Operating CF |
11.98 | 23.69 | (19.35) | 1.52 | (1.17) | 3.24 | 2.62 | 1.75 | 2.21 | 2.01 |
EV/FCF |
12.64 | 25.27 | (17.65) | 1.54 | (0.97) | 2.91 | 2.45 | 1.69 | 1.84 | 1.74 |
Quick Ratio |
9.63 | 6.94 | 6.01 | 10.24 | 8.40 | 8.53 | 7.96 | 8.76 | 9.69 | 19.95 |
Current Ratio |
9.70 | 6.98 | 6.04 | 10.26 | 8.45 | 8.58 | 8.11 | 9.02 | 9.97 | 20.15 |
Net Debt/EBITDA |
134.07 | 13.46 | 32.49 | (15.05) | 32.11 | 35.77 | 20.20 | 82.46 | 22.11 | (8.53) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.33% | 0.43% | 0.37% | 0.31% | 0.11% | 0.00% | 0.15% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.20 | 0.13 | 0.24 | 0.24 | 0.09 | 0.09 | 0.10 | 0.05 | 0.06 | 0.30 |
Operating CF/Net income |
4.43 | 1.27 | 4.87 | 21.41 | 1.40 | 4.88 | 2.30 | (1.92) | (4.32) | (0.80) |
Capex/Depreciation |
(1.14) | (1.73) | (2.70) | (3.67) | (4.89) | (1.67) | (0.55) | (0.39) | (1.80) | (0.24) |
Interest Coverage |
(6.79) | (2.94) | (16.37) | 6.16 | (1.17) | (5.36) | (15.13) | (33.78) | (112.78) | 103.05 |
| 9.60% | (13.19%) | (2.68%) | 7.21% | (11.13%) | (3.95%) | (7.94%) | 8.06% | 2.60% | 10.68% | |
| 7.07% | (9.86%) | (2.19%) | 3.95% | (5.24%) | (1.93%) | (4.13%) | 4.72% | 1.74% | 8.72% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.88% |
Return on Tangible Assets |
5.88% | (11.10%) | (2.58%) | 2.80% | (6.31%) | (2.33%) | (5.63%) | 5.95% | 2.37% | 10.67% |
Average Days of Receivables |
47.87 | 93.05 | 34.23 | 30.95 | 118.75 | 96.48 | 48.08 | 100.32 | 115.67 | 17.04 |
Research and Development Expense of Revenue |
92.06% | 140.14% | 101.58% | 47.70% | 98.76% | 101.42% | 101.94% | 100.65% | 121.70% | 41.31% |
Selling, General and Administrative Expense of Revenue |
15.52% | 17.46% | 12.51% | 10.97% | 34.93% | 43.49% | 57.89% | 55.88% | 48.77% | 13.79% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.05 | 0.05 | 0.06 | 0.00 |
Share Based Compensation of Revenue |
7.28% | 10.61% | 8.42% | 4.27% | 15.08% | 14.59% | 17.52% | 23.66% | 7.21% | 2.16% |
Graham Net Nets |
0.25 | 0.26 | 0.27 | 0.25 | 0.41 | 0.76 | 0.73 | 0.85 | 1.37 | 1.14 |
Graham Number |
0.00 | 0.00 | 0.00 | 56.97 | 0.00 | 0.00 | 0.00 | 50.47 | 0.00 | 0.00 |
Earnings Yield |
(3.49%) | (2.04%) | (0.78%) | 1.25% | (5.42%) | (3.38%) | (7.73%) | (5.68%) | 8.63% | (1.40%) |
Free Cash Flow Yield |
4.93% | 2.66% | (3.86%) | 29.73% | (9.20%) | (18.40%) | (19.41%) | (30.74%) | (56.90%) | (37.55%) |
Revenue per Share |
3.67 | 3.56 | 7.20 | 17.42 | 9.31 | 8.76 | 8.10 | 3.94 | 4.53 | 19.10 |
Operating CF per Share |
5.80 | (3.36) | (3.23) | 62.37 | (7.50) | (9.10) | (8.03) | (6.67) | (5.26) | (4.42) |
Capex per Share |
(0.12) | (0.17) | (0.31) | (0.89) | (1.60) | (1.05) | (0.58) | (0.28) | (1.35) | (0.23) |
Free Cash Flow per Share |
5.68 | (3.53) | (3.54) | 61.49 | (9.10) | (10.15) | (8.61) | (6.95) | (6.60) | (4.65) |
Cash per Share |
23.73 | 26.30 | 29.25 | 112.38 | 90.60 | 84.95 | 65.66 | 60.53 | 51.87 | 51.47 |
Shareholders Equity per Share |
18.37 | 23.12 | 27.52 | 55.90 | 46.87 | 47.75 | 40.51 | 45.92 | 47.57 | 55.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.37 | 23.12 | 27.52 | 55.90 | 46.87 | 47.75 | 40.51 | 45.92 | 47.57 | 55.56 |
Free Cash Flow |
259.64 | (174.59) | (184.45) | 3,542.48 | (592.40) | (664.55) | (565.52) | (457.61) | (435.15) | (306.44) |
Working Capital |
999.75 | 1,159.63 | 1,309.67 | 5,929.43 | 5,407.73 | 5,081.86 | 3,913.40 | 3,715.93 | 3,251.03 | 3,311.15 |
Capital Expenditures |
(5.28) | (8.40) | (16.20) | (51.17) | (104.25) | (68.48) | (38.15) | (18.23) | (88.85) | (15.16) |
Net Current Asset Value |
755.36 | 1,043.67 | 1,303.36 | 2,993.73 | 2,652.39 | 2,735.39 | 2,137.25 | 2,489.03 | 2,273.14 | 3,291.02 |
EV/EBIT |
69.80 | 0.00 | 0.00 | 13.18 | 0.00 | 9.85 | 4.91 | 6.03 | 10.04 | 4.41 |
Capex to Sales |
0.03 | 0.05 | 0.04 | 0.05 | 0.17 | 0.12 | 0.07 | 0.07 | 0.30 | 0.01 |
Price to Operating Income |
112.01 | 0.00 | 0.00 | 28.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.28 | 0.26 | 0.22 | 0.19 | 0.18 | 0.25 | 0.43 | 0.35 | 0.37 | 0.69 |
Cash ROIC |
13.50% | (7.14%) | (6.23%) | 36.45% | (6.60%) | (7.63%) | (8.09%) | (6.52%) | (6.64%) | (4.34%) |
Accounts Receivable Turnover |
9.18 | 5.27 | 9.37 | 16.68 | 4.29 | 3.29 | 4.80 | 3.67 | 3.60 | 16.42 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 | 0.00 | 0.30 | 0.30 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.32 | 0.00 | 0.56 | 0.83 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30,789.92 | 4,492.63 | 0.00 | 1,035.20 | 1,284.51 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,608.70 | 1,599.28 | 0.00 | 535.96 | 276.09 |
Average Receivables |
18.27 | 33.46 | 40.07 | 60.14 | 141.07 | 174.35 | 110.88 | 70.71 | 82.92 | 76.63 |
Average Payables |
33.67 | 43.93 | 67.33 | 121.03 | 178.78 | 179.75 | 159.61 | 151.49 | 126.66 | 112.70 |
Average Inventory |
0.35 | 0.32 | 0.16 | 0.00 | 0.00 | 12.17 | 40.05 | 67.91 | 67.73 | 40.42 |
Average Assets |
845.09 | 1,326.35 | 1,576.96 | 4,248.44 | 6,664.10 | 6,337.70 | 5,566.07 | 4,852.06 | 4,595.64 | 4,164.70 |
Average Common Equity |
622.44 | 991.71 | 1,288.94 | 2,327.38 | 3,135.54 | 3,088.85 | 2,894.39 | 2,843.53 | 3,080.21 | 3,397.92 |
Columns are period end dates